Professor Tschöp is an internationally recognised diabetes expert. He heads the Institute for Diabetes and Obesity (IDO) at the Helmholtz Zentrum München and is the scientific director of the Helmholtz Diabetes Center (HDC). The Alexander von Humboldt Professor also holds the Chair of Metabolic Diseases at the Technische Universität München (TUM). His research work focuses on the molecular foundations of the control of fat and sugar metabolism, with the objective of obtaining a better understanding of diabetes and obesity, two widespread diseases, in order to develop new approaches to personalised therapy. Prof. Tschöp has already received multiple distinctions in the framework of his research activities. In addition to the Humboldt Professorship, he has also received the Outstanding Scientific Achievement Award from the American Diabetes Association (ADA) and the Werner-Creutzfeldt Prize from the Deutsche Diabetes Gesellschaft (DDG).
Prof. Tschöp's mission: finding a cure for diabetes. He continually campaigns for scientific progress in diabetes research. This also includes a series of diabetes conferences that, in cooperation with Nature Medicine, he initiated and is heading. The first conference in this series is to be held in the Residenz palace in Munich from 22-24 September. The Helmholtz-Nature Medicine Diabetes Conference serves as a forum where scientists and experts can network and exchange scientific information. The pressing issues and challenges with regard to type 2 diabetes will be faced together in an interactive dialogue, and new preventive approaches and future therapy concepts will be developed.
To the Conference website.
Further information
About the German National Academy of Sciences (Leopoldina): The Leopoldina was founded in 1652 as a society for the natural sciences and medicine and currently has more than 1,400 members from Germany and other countries. It is Germany's oldest academy and was named the National Academy of Sciences in 2008 by Germany's federal and Land governments. The Leopoldina represents the German scientific community in international committees and carries out a science-based consultation function for the political sector and society.
Portrait of the researcher Prof. Tschöp: http://www.helmholtz-muenchen.de/forschung/forschungsexzellenz/forscherportraets/prof-dr-matthias-tschoep/index.html
To the press release for the 1st Annual Helmholtz-Nature Medicine Diabetes Conference.
As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München has about 2,100 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum München is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 34,000 staff members. http://www.helmholtz-muenchen.de
The German Center for Diabetes Research (DZD) brings together experts in the field of diabetes research and interlinks basic research, epidemiology and clinical applications. Members are the German Diabetes Center in Düsseldorf, the German Institute of Human Nutrition (DIfE) in Potsdam-Rehbrücke, Helmholtz Zentrum München – German Research Center for Environmental Health, the Paul Langerhans Institutes of the University Hospital Carl Gustav Carus in Dresden and the University of Tübingen, as well as the Gottfried Wilhelm Leibniz Association and the Helmholtz Association of German Research Centres. The objective of the DZD is to find answers to open questions in diabetes research by means of a novel, integrative research approach and to make a significant contribution to improving the prevention, diagnosis and treatment of diabetes mellitus. http://www.dzd-ev.de
The Institute of Diabetes and Obesity (IDO) studies the diseases of the metabolic syndrome by means of systems biological and translational approaches on the basis of cellular systems, genetically modified mouse models and clinical intervention studies. It seeks to discover new signaling pathways in order to develop innovative therapeutic approaches for the personalized prevention and treatment of obesity, diabetes and their concomitant diseases. IDO is part of the Helmholtz Diabetes Center (HDC).